Scholarlink

<p>Combinations of therapeutic agents can improve anticancer efficacy and overcome the limitations of single-agent treatments. This study utilizes a mouse model of Ehrlich ascites carcinoma (EAC) to investigate the anticancer potential of melatonin-selenium nanoparticles (MSeNPs). Biochemical assays, flow cytometry, histopathology, and ultrastructural analyses were used to evaluate the impact of MSeNPs on tumor growth, organ function, inflammation, angiogenesis, and cell death in EAC-bearing mice. Treatment with MSeNPs resulted in an 84% reduction in tumor volume and improved liver and kidney function, as indicated by reduced serum ALT, AST, urea, and creatinine levels. The expression of VEGF and TNF-α was significantly reduced, indicating strong anti-angiogenic and anti-inflammatory properties. Flow cytometry revealed a shift of tumor cells toward late apoptosis with reduced necrosis. Histopathological and ultrastructural analyses showed reduced EAC cell infiltration and restoration of liver architecture. Compared to melatonin or selenium monotherapies, MSeNPs exhibited superior anticancer action by combining pro-apoptotic, anti-inflammatory, and anti-angiogenic properties. These findings highlight MSeNPs as a promising nanotherapeutic strategy for more effective cancer treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo evaluation of the anticancer efficacy of melatonin–selenium nanoparticles in a mouse model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Hanaa M. Morad,
  • A. F. Abdel-Aziz,
  • Mai M. Madkour

摘要

Combinations of therapeutic agents can improve anticancer efficacy and overcome the limitations of single-agent treatments. This study utilizes a mouse model of Ehrlich ascites carcinoma (EAC) to investigate the anticancer potential of melatonin-selenium nanoparticles (MSeNPs). Biochemical assays, flow cytometry, histopathology, and ultrastructural analyses were used to evaluate the impact of MSeNPs on tumor growth, organ function, inflammation, angiogenesis, and cell death in EAC-bearing mice. Treatment with MSeNPs resulted in an 84% reduction in tumor volume and improved liver and kidney function, as indicated by reduced serum ALT, AST, urea, and creatinine levels. The expression of VEGF and TNF-α was significantly reduced, indicating strong anti-angiogenic and anti-inflammatory properties. Flow cytometry revealed a shift of tumor cells toward late apoptosis with reduced necrosis. Histopathological and ultrastructural analyses showed reduced EAC cell infiltration and restoration of liver architecture. Compared to melatonin or selenium monotherapies, MSeNPs exhibited superior anticancer action by combining pro-apoptotic, anti-inflammatory, and anti-angiogenic properties. These findings highlight MSeNPs as a promising nanotherapeutic strategy for more effective cancer treatment.

Graphical Abstract